Starting Simple: Tell Us About Your Program

• What phase is the therapy you’re supporting currently in? Options: Pre-Clinical / IND-enabling, Phase 1, Phase 2, Pivotal / Phase 3, Commercial launch, Other
• What type(s) of cell therapy are you running (select all that apply)? Options: Autologous CAR-T, Allogeneic cell therapy, TIL / tumor-infiltrating lymphocytes, Stem cell / HSC, Gene-modified cells, Other
• How many patient shipments do you expect per month once the program scales? Options: 1–5, 6–20, 21–50, 51–200, 200+
• Which geographies will regularly appear in your vein-to-vein flows? Options: Domestic only, US ↔ Canada, North America, EMEA, APAC, Global multi-region
• Who within your organization will own day-to-day logistics decisions and who signs commercial commitments? (name/role)

Are You Comfortable Betting a Patient’s Treatment on Your Current Logistics?

• How often have you seen a temperature excursion or thermal anomaly that required product disposition or re-work? Options: Never, Rarely (1–2 times), Occasionally (3–10 times), Frequently (10+ times)
• Which failure modes worry you most right now (pick all that resonate)? Options: Temperature excursions, Chain-of-identity errors, Customs or cross-border delays, Documentation gaps, Courier no-shows / delays, Facility acceptance issues
• Can you describe a specific incident or near-miss and the downstream impact it caused?
• When a logistics failure happens, how long does it typically take to identify the root cause and notify clinical/regulatory teams? Options: <1 hour, 1–6 hours, 6–24 hours, 24–72 hours, >72 hours
• When those incidents occur, what feelings or concerns surface internally (patient harm worry, audit risk, reputational pressure)? Options: Patient harm worry, Regulatory/audit anxiety, Reimbursement risk, Operational frustration, Investor concern, Other

Where the Risk Really Lives — Hidden Bottlenecks We Should Call Out

• Which part of your current end-to-end flow surprises you the most with variability or hidden handoffs? Options: Collection site coordination, Cryopreservation at clinic, Transport to manufacturer, Manufacturing release to return, Customs clearance, Local receiving at treating center
• How predictable are collection-site behaviors (e.g., paperwork completeness, timely phone confirmations) across your network? Options: Highly consistent, Mostly consistent with occasional outliers, Highly variable by site, We don’t have good visibility
• Where do you see the most frequent documentation or chain-of-custody breakdowns (labeling, manifests, signatures, electronic records)? Options: Labeling errors, Missing signatures, Incomplete manifests, Telemetry gaps, Mismatched patient IDs, Other
• How long has this variability been affecting your operations and what mitigation have you tried so far?
• Who internally is responsible for escalation when a chain-of-identity or temperature issue arises, and are they empowered to make disposition calls? Options: Clinical Ops, Technical Ops, QA/Regulatory, Supply Chain VP, Cross-functional committee, Not clearly defined

What Would a Zero-Excursion World Actually Change for You?

• If you could guarantee zero thermal excursions and perfect chain-of-identity for every shipment, what would that free you to stop worrying about?
• Which measurable outcomes would prove the solution is working for you (pick up to 3)? Options: Zero product loss due to temperature, 100% chain-of-identity verified, On-time delivery rate, Customs clearance within SLA, Regulatory audit pass with no findings, Reduced operational staffing hours
• How would those outcomes change clinician, patient, or investor conversations?
• What’s the one metric your leadership watches that would determine whether a new logistics partner is a success? Options: Cost per shipment, On-time delivery %, Excursion incidents per 1,000 shipments, Audit findings, Time-to-treatment delay rate
• If we could shrink your end-to-end cycle time by 20%, how would you redeploy the time or resources saved? Options: More patients per week, Faster regulatory filings, Reduce headcount, Invest in new trials, Other

What Would You Need to Trust an External Vein-to-Vein Partner?

• How would you prioritize these trust signals when evaluating a logistics vendor? Options: Regulatory accreditations, Operational track record (shipments), Telemetry & real-time visibility, SLA & contractual liability, On-the-ground staffing & presence, Customs expertise
• Which certifications or qualifications are non-negotiable for you (select all that apply)? Options: FDA registration, AABB accreditation, ISO 9001/ISO 13485, GDP/GMP adherence, Customs brokerage licenses, Other
• What level of telemetry and dashboard access do you require during transit (real-time temp + GPS, alerts, raw data access, API integration)? Options: Real-time temp + GPS with alerts, Daily summary reports, Raw telemetry download after shipment, API integration into our systems, Only exception reporting
• How much commercial flexibility do you need (pilot pricing, capped liability, scalable rates) before you’ll sign a multi-year agreement? Options: Pilot-only, Pilot then commercial, Need capped liability, Need flexible scaling, Price is secondary to reliability
• Would you expect the vendor to participate in regulatory audits and, if so, what documentation access would be required? Options: Yes — full documentation access, Yes — redacted documents, Limited to summary evidence, Depends on audit scope

The Real Cost of a Logistics Failure (Not Just Dollars)

• When you think beyond replacement cost, which consequence of a failure feels most consequential to the team? Options: Patient care delay/harm, Regulatory citation, Clinical trial disruption, Reputational damage, Financial penalty/reimbursement loss
• Have you experienced regulatory findings tied to logistics or documentation in the last three years? If yes, what was the nature and outcome? Options: Yes — documentation-related, Yes — temperature/quality-related, Yes — customs/import-related, No, Prefer not to say
• How do you currently quantify the cost of a lost or compromised patient shipment (direct costs, study delays, chance of patient re-dosing)?
• Who in your organization feels the greatest pressure after an incident (clinical leadership, supply chain, QA, CFO)? Options: Clinical leadership, Supply Chain, QA/Regulatory, Finance/CFO, Commercial leadership
• What reporting cadence and content would make leadership feel reassured during a logistics disruption? Options: Immediate alert + hourly updates, Immediate alert + daily summary, Root-cause report within 72 hours, Ad-hoc updates as requested

How Ready Are You to Onboard and Run Qualification Tests?

• If we proposed a 2–4 month onboarding with qualification runs, how realistic is that timeline for your team? Options: Immediately achievable, Achievable with internal reprioritization, Requires >4 months, Not sure / need to discuss
• Which of these onboarding items are already in place versus blockers (select all that apply)? Options: Aligned SOPs, Facility qualifications, Chain-of-identity workflows, Customs paperwork templates, Data sharing agreements, None of the above
• Who would be the primary point(s) of contact for qualification planning, and who must sign off on acceptance criteria?
• What acceptance criteria do you require for a successful qualification run (temperature profile, GPS accuracy, paperwork completeness, customs time)? Options: Temperature within spec, Telemetry completeness, No chain-of-identity exceptions, Customs clearance within SLA, On-time handoffs
• What internal approvals (QA, legal, clinical) are often the slowest, and how long do they typically take? Options: QA, Legal, Clinical Ops, Supply Chain, Regulatory

First Practical Steps — What Would Make a Pilot Easy to Say Yes To?

• What would a low-risk pilot look like to you (scope, sample types, number of shipments, regions)? Options: Domestic single route, 3–5 shipments, Domestic multi-site, 5–10 shipments, Cross-border single lane, 3–5 shipments, Full process end-to-end, small volume
• Which success signals from a pilot would convince leadership to move to a contract (pick top 3)? Options: Zero temperature exceptions, Complete chain-of-identity audit trail, Timely customs clearance, Positive internal stakeholder feedback, Clear SOP alignment
• What contractual protections would make you comfortable running a pilot (capped liability, service credits, indemnity, audit rights)? Options: Capped liability, Service credits, Indemnity clause, Right to audit, None needed for pilot
• Who are the decision-makers and influencers we should include in a kickoff so approvals don’t stall?
• Realistically, when could we schedule the first qualification shipment if we agreed scope this week? Options: Within 2 weeks, 2–4 weeks, 1–2 months, >2 months

• Pre-Work & Problem Confirmation
• Failure-Mode Walkthrough (Customer Scenarios)
• Proof Mapping: Telemetry, SOPs & Simulations
• Validation, Agreement & Next Steps

• Session Framing & Rules
• All attendees to confirm final participant list and any technical SMEs required for failure-mode sessions.
• Introductions & Objective
• Validate that vendor controls directly eliminate or mitigate the customer's documented failure modes.
• Obtain explicit customer agreement or exception list for each failure mode's proposed control set.
• Identify any technical or regulatory gaps that must be proven with telemetry or simulations.
• Vendor to produce a failure-mode traceability matrix mapping each customer incident to the specific control and evidence to be shown.
• Customer to list any country-specific customs exceptions and provide local contacts if available.
• Schedule a Proof Mapping session that will include telemetry samples and SOP excerpts for the identified gaps.
• Deliver concrete data and SOP proof that the controls achieve the future-state acceptance criteria.
• Opening: Acceptance Criteria Recap
• Agree the evidence package required for each acceptance criterion and any format or retention requirements.
• Confirm that the tabletop responses meet the customer's decision gates and timelines or capture specific adjustments.
• Vendor to share anonymized telemetry files and annotated SOP excerpts in the shared workspace within 48 hours.
• Customer to confirm the evidence package format and any internal reviewers who must approve it prior to qualification.
• Jointly create a short checklist of validation checkpoints to be used during the qualification run.
• Recap: Current State, Consequence, Future State
• Obtain mutual decision to proceed to Solution Scope and schedule the qualification run with dates and owners.
• Finalize and sign off on measurable acceptance criteria and required evidence for qualification.
• Assign accountable owners for each responsibility and capture any remaining exceptions with mitigation plans.
• Produce a joint Solution Experience Summary document that includes the agreed current state, quantified consequences, future state, acceptance criteria, and owners for signature.
• Schedule the qualification run date(s) and circulate a detailed runbook and participant list at least two weeks prior to the run.
• Vendor to deliver any outstanding compliance evidence (FDA registration, AABB accreditation excerpts) required for internal approvals.
• Agree a single-sentence current state that all participants can repeat back.
• Quantify the business, clinical, and regulatory consequences of the top failure modes in explicit terms.
• Define a one-sentence future operational outcome with measurable acceptance criteria.
• Confirm required pre-work artifacts are available for the Solution Experience sessions.
• Customer to upload the 1-page Current State & Impact brief and any incident reports to the shared workspace.
• Vendor to prepare a one-page mapping template that links current-state failures to operational metrics for the next meeting.
• Telemetry & Incident Case Studies
• Temperature Excursion: Diagnosis
• Acceptance Criteria & Evidence Review
• One-Sentence Current State
• Roles, Responsibilities & SLA Implications
• Consequence Quantification
• SOP & Role Mapping
• Temperature Excursion: Proof
• Define Future Operational Outcome
• Risk Exceptions & Mitigations
• Temperature Excursion: Validation
• Tabletop Simulation (what-if)
• Validation Checkpoints & Evidence Package
• Decision & Scheduling
• Verify Pre-Work Evidence
• Chain-of-Identity: Diagnosis
• Chain-of-Identity: Proof
• Chain-of-Identity: Validation
• Customs/International Delay: Diagnosis
• Customs/International Delay: Proof
• Customs/International Delay: Validation & Triage
• Wrap & Outstanding Questions

• Door‑to‑door cryogenic transport (liquid‑nitrogen vapor shippers)
• Continuous GPS and temperature telemetry logging per shipment
• Chain‑of‑identity physical tagging and digital documentation
• Chain‑of‑custody transfer documentation at each handoff
• Customs clearance and regulatory import/export handling
• On‑site apheresis collection and cryopreservation support
• Controlled‑rate freezing and validated cryostorage
• Validated shipping container provisioning and conditioning
• Expedited reroute and recovery for delayed shipments
• Clinical‑site thawing and verified patient handoff
• Regulatory‑ready shipment dossier and release documentation
• Temperature‑excursion recovery disposition and quarantine handling

Door‑to‑door cryogenic transport (liquid‑nitrogen vapor shippers)

• What regions will require door‑to‑door cryogenic service? Options: Domestic (single country), Regional (multiple countries, same trade zone), Global / cross‑continent
• What is your expected shipping cadence and volume (average and peak)? Options: 1-5 shipments/month, 6-20 shipments/month, 21-100 shipments/month, 100+ shipments/month
• What is the maximum tolerated door‑to‑door transit time for patient material (hours)? Options: <8 hours, 8-24 hours, 24-48 hours, 48+ hours / case-by-case
• Who will be responsible for scheduling and dispatch at collection and receiving sites? Options: Customer, Vendor, Shared (predefined SLA)
• Are there specific site access constraints we must accommodate (curfews, security checks, limited dock hours)?
• Do you require white‑glove services (onsite pickup handling, escort, or assisted loading) for any sites? Options: Yes, No

Continuous GPS and temperature telemetry logging per shipment

• Which telemetry data do you require in real time or post‑trip reports? Options: GPS location, Temperature profile, Shock/tilt events, Battery/health status, Other
• What sampling frequency or granularity do you require for temperature logging? Options: Real‑time continuous, Every 1 minute, Every 5 minutes, Every 15 minutes, Other
• Who should receive telemetry alerts and what escalation path is preferred?
• Do you require integration of telemetry into your MES/track‑and‑trace system or a vendor portal? Options: Yes — API integration, Yes — CSV/SFTP reports, No — vendor portal access is sufficient
• What retention period do you need for telemetry and shipment logs (regulatory and QA recordkeeping)? Options: 1 year, 2-5 years, 5+ years, Follow customer's SOP
• Are there specific alarm thresholds (e.g., temperature excursion limits) we should configure?

Chain‑of‑identity physical tagging and digital documentation

• Do you have an existing chain‑of‑identity (COI) numbering or barcode standard we must adopt? Options: Yes — provide standard, No — vendor to propose standard
• Which physical tag media do you prefer for COI (tamper‑evident seals, barcode labels, RFID wristbands)? Options: Tamper‑evident seals, Barcoded labels, RFID tags, Other
• What digital documentation is required to accompany COI (PDF manifest, signed chain log, EHR integration)? Options: PDF manifest, Digitally signed chain log, EHR/LIMS integration, Other
• Who owns final verification of COI at each handoff (collection tech, courier, receiving site)? Options: Collection site, Courier, Receiving/manufacturing site, Shared — specify role matrix
• Do you require photographs or biometric confirmations at collection/receipt to verify identity? Options: Yes — photos, Yes — biometric, No
• Are there regulatory or sponsor-specific naming conventions or redaction needs for documentation?

Chain‑of‑custody transfer documentation at each handoff

• At which handoff points do you require signed chain‑of‑custody (pickup, transfer, customs, delivery)? Options: Pickup only, Pickup and delivery, Every handoff including intermediate carriers and customs, Custom selection — specify
• What format do you prefer for custody records (signed paper manifest, e‑signature, timestamped digital log)? Options: Signed paper manifest, E‑signature with timestamp, Timestamped digital log (vendor portal), Other
• Who is authorized to sign custody at each site and do we need a master list of authorized signatories? Options: Yes — provide authorized signatory list, No — site will provide on demand
• Do custody forms need to be uploaded to your QA system automatically after each shipment? Options: Yes — automated upload, No — manual upload suffices, Optional — both available
• Do you require time‑stamped photo evidence of handoffs or in‑person witness notes? Options: Yes, No
• Are there any language, redaction, or PII/PHI constraints for custody documentation?

Customs clearance and regulatory import/export handling

• Will shipments cross international borders, and if so which origin/destination country pairs are anticipated? Options: Domestic only, Specific country pairs — list required, Multiple unpredictable cross‑border routes
• Do you have an established customs broker or do you require the vendor to provide brokerage services? Options: Customer broker (provide details), Vendor to provide broker, Open to either
• Are there pre‑approved import licenses, permits, or clinical trial authorizations required for your material? Options: Yes — customer will provide copies, No — none required, Unknown — need assessment
• What customs SLA is acceptable for clearance (hours to clear) and what are permitted contingency actions if delayed?
• Do you require vendor responsibility for customs fines, duties, or regulatory holds, or will the customer accept shared/liability terms? Options: Vendor assumes responsibility, Customer assumes responsibility, Shared — specify
• Do you need pre‑cleared documentation packets assembled (commercial invoice, COO, permits, clinical letters)? Options: Yes — vendor assembles, No — customer provides

On‑site apheresis collection and cryopreservation support

• Which collection sites require on‑site support and what are their addresses and site contacts?
• What level of on‑site support is needed (training only, full apheresis assistance, cryopreservation at site)? Options: Training and SOP alignment, Apheresis technician support, On‑site cryopreservation processed by vendor, Other
• Do your sites have validated freezers/cryopreservation equipment or should vendor bring portable equipment? Options: Site has validated equipment, Vendor to supply portable validated equipment, Mixed — details required
• Who provides and signs off on collection SOPs, informed consent and collection checklists? Options: Customer, Vendor, Joint sign‑off
• Are there preferred schedule windows for collections and turnaround expectations between collection and handover to courier?
• Do you require competency records and training documentation for on‑site vendor staff? Options: Yes, No

Controlled‑rate freezing and validated cryostorage

• Do you require vendor‑run controlled‑rate freezing or will material arrive pre‑frozen? Options: Vendor performs controlled‑rate freezing, Customer supplies pre‑frozen material, Both depending on site
• What storage duration and access patterns (short term <30 days vs. long term >30 days) do you anticipate? Options: Short term (<30 days), Medium term (30-365 days), Long term (>365 days)
• What qualification and monitoring evidence do you require for cryostorage (AABB/FDA register, temperature logs, backup LN2)? Options: AABB accreditation/FDA registration, Continuous monitoring & alarm logs, Backup LN2 and contingency plan, All of the above
• Who owns lot traceability and frozen inventory reconciliation (vendor inventory system vs customer LIMS)? Options: Vendor inventory system, Customer LIMS, Dual reconciliation (both)
• What acceptance criteria define an acceptable freeze profile (cooling rates, nucleation control, residual viability metrics)?
• Do you require sample aliquoting, relabeling, or secondary containment while in storage? Options: Yes — specify, No

Validated shipping container provisioning and conditioning

• How many validated shipping containers do you need provisioned initially and as ongoing fleet? Options: 1-5, 6-20, 21-100, 100+
• Do you require vendor validation reports for each container type (IQ/OQ/PQ) prior to qualification runs? Options: Yes — full validation package, Summary validation acceptable, No — use vendor standard
• What conditioning protocol do you require before shipment (pre‑conditioning hold time, LN2 fill levels)?
• Will containers be branded or require specific external labeling or tamper seals? Options: Yes — branded/labeling required, No — standard vendor labels
• Do you require documented chain‑of‑custody for container provisioning and turnaround (cleaning, conditioning, certification)? Options: Yes, No
• Are there site constraints for container drop/pick (size, weight limits, return timelines)?

Expedited reroute and recovery for delayed shipments

• What maximum delay tolerance triggers expedited reroute or recovery actions? Options: <2 hours, 2-6 hours, 6-24 hours, Case‑by‑case
• Which recovery options are acceptable (air uplift, ground expedite, diversion to alternate site, return to origin)? Options: Air uplift, Ground expedite, Diversion to alternate site, Return to origin, Other
• Who holds authority to approve expedited recovery costs and decisions? Options: Customer, Vendor per SLA, Pre‑approved spend thresholds
• Do you require pre‑approved contingency routes and alternate receiving sites to be documented in advance? Options: Yes — provide list, No — handle ad hoc
• Are there insurance or liability limits required for recovery events? Options: Yes — specify limits, No — vendor standard
• Do you require post‑event root cause analysis and formal CAPA documentation after any recovery incident? Options: Yes, No

Clinical‑site thawing and verified patient handoff

• Will thawing occur at clinical sites, at manufacturing sites, or both? Options: Clinical sites only, Manufacturing sites only, Both
• Do clinical sites require vendor personnel to perform or supervise thaw and patient handoff? Options: Vendor to perform thaw, Vendor to supervise site staff, Site performs independently
• What verification steps are required at handoff (patient ID match, temperature check, thaw time stamp)?
• Do you require a documented chain‑of‑identity reconciliation after thaw and before infusion? Options: Yes, No
• Are there site training or competency records needed for thaw procedures and handling post‑thaw material? Options: Yes, No
• What is the acceptable window between thaw completion and infusion at site (minutes/hours)? Options: <30 minutes, 30-120 minutes, 2-6 hours, Other

• Non-Disclosure Agreement (NDA)
• Master Services Agreement (MSA)
• Statement of Work (SOW)
• Service Level Agreement (SLA)
• Commercial Terms & Pricing Schedule
• Regulatory & Compliance Addendum
• Data Processing & PHI Agreement (DPA/HIPAA)
• Liability, Indemnity & Insurance Schedule
• Governance, Roles & Escalation Plan
• Acceptance Criteria & Qualification Plan
• Dependencies & Third‑Party Services Annex
• Customs & Cross‑Border Responsibilities
• Implementation & Onboarding Timeline
• Termination, Exit & Sample Disposition Plan

• Success Outcomes Review
• Lessons Learned & Incident RCA
• Operational Escalation & Shared Channel Setup
• Continuous Improvement & Optimization Workshop
• Executive Closeout & Strategic Next Steps

• Publish the CI backlog with ICE/priority scores and pilot charters to the shared workspace.
• Schedule and execute validation activities (e.g., pilot shipments) required to close CAPAs.
• Purpose & Channel Options
• Create and provision a shared operational channel with the right participants and permissions.
• Agree and document an escalation matrix with SLAs and on-call roles for both vendor and customer.
• Validate telemetry access and run a live tabletop to confirm the playbook works in practice.
• Provision shared channel and invite defined participants with correct permission levels.
• Publish the agreed escalation matrix, contact list, and SLA table in the shared channel and in the runbook.
• Configure telemetry alerts to the shared channel and run an end-to-end test alert.
• Current Performance Snapshot
• Produce a prioritized continuous improvement backlog with 1-3 agreed pilots and measurable success criteria.
• Assign owners and timelines for pilots and establish a recurring CI governance cadence.
• Ensure every proposed improvement includes a validation plan to prove risk reduction or cost/time savings.
• Introductions & Objectives
• Schedule pilot start dates and necessary resource commitments (equipment, test shipments, training).
• Define KPIs that will be used to evaluate pilot success and add them to the KPI dashboard.
• Executive Summary of Outcomes
• Obtain executive confirmation that success signals met business objectives and agree next strategic steps.
• Secure commitments for renewal, scale, or a funded pilot to pursue identified optimization opportunities.
• Ensure executives understand remaining risks and have visibility to mitigation plans and owners.
• Deliver an executive one-page summary and the full closeout package (acceptance report, RCA, CI backlog).
• Provide a commercial proposal or statement of work for any agreed expansion or renewal terms.
• Schedule the first Quarterly Business Review (QBR) and assign an ongoing CSM and technical owner.
• Validate measured outcomes against each documented success signal and obtain explicit customer acceptance or list of remediation items.
• Surface any unresolved risks that would prevent continued live patient shipments and assign accountable owners.
• Agree on concrete next steps, timelines, and criteria for closing any remediation items.
• Publish formal Acceptance Report summarizing KPI results, incidents, and customer sign-off status.
• Update shared KPI dashboard with final datasets and access permissions for the customer operations team.
• Create remediation task list for any failed success signals with owners, target dates, and escalation path.
• Incident Inventory & Timeline
• Identify root causes for each incident and agree on CAPAs with clear owners and timelines.
• Ensure CAPAs include validation steps that prove the issue is resolved.
• Establish a documentation and training plan so lessons are institutionalized across both parties.
• Produce formal RCA documents for each incident and circulate to governance and QA teams.
• Update SOPs or work instructions identified in the CAPA within agreed timelines.
• Restate Success Signals
• Escalation Matrix & RACI
• Root Cause Analysis (5 Whys / Fishbone)
• Risk & Compliance Posture
• Present Lessons & Candidate Improvements
• Prioritization Exercise
• Telemetry & Data Access
• Customer Experience & Satisfaction
• Corrective and Preventive Actions (CAPA)
• Quantitative Outcomes Review
• Exceptions & Incidents
• Validation of Proposed Changes
• Pilot Charters & Success Metrics
• Strategic Opportunities: Scale & Efficiency
• Playbook Walkthrough & Tabletop Test
• Channel Governance & Retention
• Cadence & Governance for CI
• Customer Confirmation & Decision
• Documentation & Dissemination Plan
• Commercial/Contractual Next Steps
• Next Steps & Ownership
• Executive Decisions & Commitments